Biology subjects

Schanstra, J. P.

Publications and source records attributed to Schanstra, J. P..

5 recordsLinked to original sources

bioRxiv2026

Systematic comparison of gliflozins identifies a selective anti-calcifying effect of canagliflozin beyond canonical SGLT2 inhibition

Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) provide important cardiorenal benefits in chronic kidney disease (CKD), but their effects on vascular calcification remain conflicting. Whether potential anti-calcifying effects are shared across gliflozins or involve mechanisms beyond canonical SGLT2 inhibition is unknown. Methods: We systematically compared canagliflozin, dapagliflozin and empagliflozin in a high-phosphate diet-induced mouse model of vascular calcification and complementary ex vivo and in vitro models, including rodent and human vascular tissues and vascular smooth muscle cells (VSMCs). Aortic transcriptional response was investigated by RNA sequencing. VSMC calcification, proliferation, migration, viability, glucose uptake and bioenergetics were investigated using complementary cellular assays, including OsteoSense staining, Annexin V/propidium iodide staining, radiolabeled 2-deoxyglucose uptake and Seahorse ATP rate analysis. SGLT2/1 expression was examined by RT-qPCR, Western blotting and immunofluorescence. We also evaluated sotagliflozin, a dual SGLT1/2 inhibitor, and mizagliflozin, a selective SGLT1 inhibitor. Results: Among the three gliflozins, only canagliflozin significantly reduced aortic calcification in vivo. Its anti-calcifying effect was also observed in rodent aortic rings, human vascular explants, cultured VSMCs and aortic rings from diabetic db/db mice. Aortic RNA-seq revealed that canagliflozin partially reversed HPD-induced transcriptional alterations, including changes in pro-calcific signaling and cellular metabolism, while some endothelial and inflammatory responses were shared among gliflozins. In mouse VSMCs, canagliflozin reduced calcification across all tested concentrations, dose-dependently decreased osteogenic marker expression, and reduced proliferation and migration. Increased apoptotic and damaged cell fractions were observed at higher concentrations, but not at lower concentrations. Canagliflozin also reduced glucose uptake and mitochondrial ATP production, without significantly affecting glycolytic ATP production. Neither dapagliflozin nor empagliflozin reproduced these cellular and metabolic effects at any of the concentrations tested. SGLT2 and SGLT1 expression was low or undetectable in vascular tissues and cells, and neither sotagliflozin nor mizagliflozin reproduced the anti-calcifying effect of canagliflozin in vivo or in vitro. Conclusions: Canagliflozin exhibits a selective anti-calcifying profile among the gliflozins tested, associated with changes in VSMC responses and cellular metabolism. These findings suggest that its vascular protective effects may involve mechanisms beyond canonical SGLT2 inhibition.

pathology↗

bioRxiv2026

Identification of the Col4a3-/- mouse as a model of chronic kidney disease-associated cachexia

Background: Cachexia is a frequent complication of advanced chronic kidney disease (CKD), i.e. renal cachexia, particularly in patients undergoing hemodialysis in whom it represents one of the strongest predictors of morbidity and mortality. Yet, our understanding of the molecular mechanisms leading to body wasting in CKD and management of cachectic patients are still poorly defined. To date, a preclinical mouse model of robust and reproducible CKD-associated cachexia is missing. Here, we assessed in a systematic manner the cachectic phenotype of the genetic Col4a3-/- mouse model of CKD. Methods: 129/SvJ Col4a3-/- male and female animals were monitored longitudinally until they developed kidney failure. Measured glomerular filtration rate (mGFR), body composition and grip strength were recorded at baseline (6 weeks of age, before onset of kidney dysfunction) and at endpoint (CKD with weight loss or 12 weeks of age). The severity of CKD was confirmed by biochemical and histological analyses. Muscle atrophy was assessed via fiber cross-sectional area analysis, atrogene expression and transcriptomics. Adipose tissue wasting was assessed by measuring adipocyte area and proteins involved in lipid synthesis and breakdown. Liver acute phase response and systemic inflammation were evaluated by measuring circulating levels of key factors using ELISA. Results: Col4a3-/- animals developed CKD (decrease in mGFR: -85%, P<0.0001) and cachexia within 8-12 weeks of age. Cachexia was characterized by a progressive loss of body weight (-17.8% +/- 1.0, P<0.0001), lean (-8.2% +/- 2.0, P<0.0001) and fat mass (-66.5% +/- 4.7, P<0.0001) associated with reduced grip strength (-24.3% +/- 0.0, P=0.0002). At the tissue level, cachexia led to muscle atrophy and induction of atrogenes. Muscle transcriptomics further validated the cachectic phenotype of the Col4a3-/-, with 47% of genes altered in a similar manner with the well-established colon-C26 mouse model of cancer cachexia. It also revealed signatures that appeared more specific to renal cachexia. Adipose tissue wasting was characterized by a depletion in fat stores, consecutive to an imbalance between proteins involved in lipogenesis and lipolysis. Cachexia in this model was also associated with the induction of acute phase response in liver, elevated circulating levels of serum amyloid A and systemic inflammation, with the induction of established cachexia mediators (IL-6, GDF-15 P<0.0001). Both male and female mice developed cachexia. Conclusions: Our data highlight the potential of using the Col4a3-/- mouse model of CKD for the future study of renal cachexia, offering a more robust alternative to classically used models of partial nephrectomy or adenine-rich diet.

pathology↗

bioRxiv2023

Integrative analysis of CAKUT multi-omics data

Congenital Anomalies of the Kidney and Urinary Tract (CAKUT) is the leading cause of childhood end-stage renal disease and a significant cause of chronic kidney disease in adults. Genetic and environmental factors are known to influence CAKUT development, but the currently known disease mechanism remains incomplete. Our goal is to identify affected pathways and networks in CAKUT, and thereby aid in getting a better understanding of its pathophysiology. Multi-omics experiments, including amniotic fluid miRNome, peptidome, and proteome analyses, can shed light on foetal kidney development in non-severe CAKUT patients compared to severe CAKUT cases. We performed FAIRification of these omics data sets to facilitate their integration with external data resources. Furthermore, we analysed and integrated the omics data sets using three different bioinformatics strategies. The three bioinformatics analyses provided complementary features, but all pointed towards an important role for collagen in CAKUT development. We published the three analysis strategies as containerized workflows. These workflows can be applied to other FAIR data sets and help gaining knowledge on other rare diseases.

systems biology↗

bioRxiv2021

Proteomic analysis of mouse kidney tissue associates peroxisomal dysfunction with early diabetic kidney disease

BackgroundThe absence of efficient inhibitors for DKD progression reflects the gaps in our understanding of DKD molecular pathogenesis. A comprehensive proteomic analysis was performed on glomeruli and kidney cortex of diabetic mice with subsequent validation of findings in human biopsies and - omics datasets aiming to better understand the underlying molecular biology of early DKD development and progression. MethodsLC-MS/MS was employed to analyze the kidney proteome of DKD mouse models: Glomeruli of Ins2Akita mice 2 month and 4 month old, and cortex of db/db mice 6 month old. Following label-free quantification, the abundance of detected proteins were correlated with existing kidney datasets and functionally annotated. Tissue sections from 16 DKD patients were analyzed by IHC. ResultsPathway analysis of differentially expressed proteins in the early and late DKD versus controls predicted dysregulation in DKD hallmarks (such as peroxisomal lipid metabolism, {beta}-oxidation and TCA cycle) supporting the functional relevance of the findings. Comparing the observed protein changes in early and late DKD, consistent upregulation of 21 and downregulation of 18 proteins was detected. Among these were downregulated peroxisomal proteins such as NUDT19, ACOX1, and AMACR and upregulated mitochondrial proteins related to aminoacid metabolism including GLS, GLDC, and GCAT. Several of these changes were also observed in the kidney cortex proteome of db/db mice. IHC of human kidney further confirmed the differential expression of NUDT19, AGPS, AMACR and CAT proteins in DKD. ConclusionsOur study shows an extensive differential expression of peroxisomal proteins in the early stages of DKD that persists regardless of the disease severity. These proteins therefore represent potential markers of early DKD pathogenesis. Collectively, essential pathways associated with peroxisomes such as lipid {beta}-oxidation, plasmalogen synthesis, aminoacid metabolism and response to oxidative stress are downregulated in early DKD, providing new perspectives and potential markers of diabetic kidney dysfunction.

systems biology↗

bioRxiv2021

Haploinsufficiency of the mouse Tshz3 gene leads to kidney dysfunction

Renal tract defects and autism spectrum disorder (ASD) deficits represent the phenotypic core of the 19q12 deletion syndrome caused by the loss of one copy of the TSHZ3 gene. While a proportion of Tshz3 heterozygous (Tshz3+/lacZ) mice display ureteral defects, no kidney defects have been reported in these mice. The purpose of this study was to characterize the expression of Tshz3 in adult kidney as well as the renal physiological consequences of embryonic haploinsufficiency of Tshz3 by analyzing the morphology and function of Tshz3 heterozygous adult kidney. Here, we described Tshz3 expression in the smooth muscle and stromal cells lining the renal pelvis, the papilla and glomerular endothelial cells (GEnCs) of the adult kidney. Histological analysis showed that Tshz3+/lacZ adult kidney had an average of 29% fewer glomeruli than wild type kidney. Transmission electron microscopy (TEM) of Tshz3+/lacZ glomeruli revealed ultrastructural defects. Compared to wild type, Tshz3+/lacZ mice showed no difference in their urine parameters but lower blood urea, phosphates, magnesium and potassium at 2 months of age. At the molecular level, transcriptome analysis identified differentially expressed genes related to inflammatory processes in Tshz3+/lacZ compare to wild type (WT; control) adult kidneys. Lastly, analysis of the urinary peptidome revealed 33 peptides associated with Tshz3+/lacZ adult mice. These results provide the first evidence that in the mouse Tshz3 haploinsufficiency leads to cellular, molecular and functional abnormalities in the adult mouse kidney.

genetics↗